4级三负乳腺癌患者通过新的药物组合获得了罕见的完全免疫反应,表明肿瘤严重萎缩,三个月后没有可检测的癌症。 A stage IV triple-negative breast cancer patient achieved a rare complete immune response with a new drug combo, showing major tumor shrinkage and no detectable cancer after three months.

在FDA扩展接入协议下,Kazia Therapeutics报告了一名IV期三阴性乳腺癌患者的罕见初始免疫完整反应,该患者接受了帕克萨利西布,布罗利祖马布和化疗治疗. Kazia Therapeutics reported a rare initial immune-complete response in a stage IV triple-negative breast cancer patient treated with paxalisib, pembrolizumab, and chemotherapy under an FDA expanded access protocol. 病人在3周内减少了86%的肿瘤,并在3个月后完成了所有损伤的代谢解析,满足了在转移性TNBC中不常见的iCR的标准。 The patient achieved an 86% tumor reduction in three weeks and complete metabolic resolution of all lesions after three months, meeting criteria for an iCR—uncommon in metastatic TNBC. 该病人仍在治疗中,并计划进行后续成像。 The patient remains on treatment with follow-up imaging planned. 该公司还宣布即将就帕萨利西布组合、遗传途径和液体生物检查研究进行科学专题介绍,重点介绍乳腺癌、免疫肿瘤学和淋巴瘤管制战略的进展情况。 The company also announced upcoming scientific presentations on paxalisib combinations, epigenetic pathways, and liquid biopsy research, highlighting progress in breast cancer, immuno-oncology, and glioblastoma regulatory strategy.